Nab-Paclitaxel and Gemcitabine
PreclinicalSmall molecule
Nab-Paclitaxel and Gemcitabine is one of 4 small molecule programs targeting Advanced Pancreatic Cancer. It is currently in Preclinical.
1
Indications
5
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
3 competitors in Advanced Pancreatic Cancer
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 2
Galeterone
LLTN PHARMACEUTICALS, INC.
Phase 2
IBI343
Innovent Biologics (Suzhou) Co. Ltd.Preclinical
Nab-Paclitaxel and Gemcitabine
PPrECOG, LLC.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Cancer2 trials
Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.
Completed·GGruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente·Phase 2·NCT02043730·124 enrolled
Pancreatic Adenocarcinoma1 trial
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Terminated·GGB002, Inc., a wholly owned subsidiary of Gossamer Bio, Inc.·Phase 1·NCT04060342·61 enrolled
Cholangiocarcinoma1 trial
Advanced Pancreatic Cancer1 trial
A Phase I/IIa Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of GKL-006 Injection in Patients With Advanced Pancreatic Cancer
Active, not recruiting·BBeijing Gene Key Life Technology Co., Ltd·Preclinical·NCT07777211·52 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPrECOG, LLC.